diaTribe Musings LIVE at ADA 2023 in San Diego

The Future of Diabetes Care

Thursday, June 22, 2023
6:30-9:00pm PDT

The Prado at Balboa Park
1549 El Prado
San Diego, California 92101

The diaTribe Foundation presented its first in-person Musings event since 2019 at the 2023 ADA Scientific Sessions. Following a festive reception, Dr. Alan Moses moderated a panel discussion to address today’s most pressing issues and the greatest opportunities for improving the lives of people with diabetes. The panel, The Future of Diabetes Care, featured leading diabetes clinician-researcher, Dr. Vanita Aroda and representatives from event sponsors Abbott, AstraZeneca, Dexcom, Novo Nordisk, and Sanofi, with additional sponsorship support provided by Lilly. More information on the panelists below.

Topics included:

The most exciting advances to watch for in technology, including non-invasive glucose monitoring devices and ketone monitoring

The incorporation of CGM data into algorithms and AI solutions to improve outcomes and the individual experiences of people living with diabetes

The ever-increasing importance of Time in Range in diabetes care

New drugs being designed to further improve glucose management and reduce the risk of acute and chronic diabetes complications

The evolution of disease modifying therapies for T1D

Diabetes remission in T2D – the role of weight and approaches to achieve weight loss

PANELISTS

Vanita R. Aroda, MD
Director of Diabetes Clinical Research, Brigham and Women's Hospital | Associate Professor of Medicine, Harvard Medical School

Vanita Aroda is the Director of Diabetes Clinical Research at the Brigham and Women's Hospital in Boston, Massachusetts, and is an Associate Professor of Medicine at Harvard Medical School. Dr. Aroda completed her training in Internal Medicine and in Endocrinology, Diabetes, and Metabolism at the University of California San Diego. Dr. Aroda has an interest and published record in diabetes prevention and novel therapeutics in diabetes and weight management. She also has an interest in understanding therapeutic interventions in large multicenter clinical trials and their applicability and integration into care. Dr. Aroda has years of experience in clinical trail conduct and leadership, has served as an investigator on the National Institutes of Health-funded GRADE, D2d, and DPROS studies, and as a national or international signatory Principal Investigator for multiple therapeutic trials. Dr. Aroda serves on the Professional Practice Committee of the American Diabetes Association and on the international ADA-EASD Consensus Group for the Management of Hyperglycemia in Type 2 Diabetes.

Scott Harper
Division Vice President, Research and Development, Abbott Diabetes Care

Since joining Abbott in 2004, Scott has been instrumental in overseeing strategy and execution for all R&D-driven products for Abbott Diabetes Care. He has been one of the driving forces behind the development and innovation of the FreeStyle Libre system, a sensor-based glucose monitoring solution that’s transforming glucose monitoring for people living with diabetes. His primary responsibility is to serve as technical lead for current and near-term products in the FreeStyle Libre system portfolio. As part of his leadership role, he is also a co-architect of the design control process, which provides a framework for all product development efforts. Scott and his team are motivated to make positive changes for those in need. He and his team of R&D program managers and systems engineers deliver new product introductions and changes to existing products – from the design inputs phase, to regulatory approval, to the product launch phase. Scott holds a bachelor’s degree in bioengineering from the University of California, San Diego.

Luigi Meneghini, MD, MBA
Head of US Diabetes Medical, Sanofi

Prior to joining Sanofi in November 2020, Luigi had been Professor of Medicine at UT Southwestern Medical Center in Dallas, Texas, where he was tasked to build a system-wide program for the Parkland Health & Hospital System to organize, integrate and optimize diabetes management among primary, specialty and acute care settings, leveraging IT and population health expertise, and community resources to chronic disease burden. Prior to moving to Dallas, Luigi spent 20 years on faculty at the University of Miami's Diabetes Research Institute where he directed clinical, research and patient and professional education programs focused on improving the lives of people with diabetes and establishing himself as a key opinion leader in the insulin management space. Luigi received his medical degree from Emory University and did his residency training (Internal Medicine) and fellowship (Endocrinology) at the University of Miami Jackson Memorial Hospital. While in Miami he earned an executive MBA in healthcare management (2000), which prepared him for his administrative and leadership roles in medicine.

Girish Naganathan
Executive Vice President and Chief Technology Officer, Dexcom

Girish Naganathan has served as Dexcom's EVP, Chief Technology Officer since October 2022. Girish is responsible for setting global strategy and direction for the Research and Development organization, driving the execution of technology roadmaps, and accelerating new product research, development, and commercialization. Girish has close to 25 years of experience spanning the Consumer Electronics, Data Storage, IoT, and Broadband industries. Prior to joining Dexcom, Girish spent over ten years at Technicolor, most recently serving as Chief Technology Officer and General Manager of the Broadband Division. In these roles, he set the company's strategic technology direction, leading product development and deploying IoT and broadband solutions across markets and industries. This work included driving innovation across multiple product lines, ensuring the success of technology acquisitions, building relationships with key customers and partners, and fostering a culture of accountability and agility. Before joining Technicolor, Girish held several leadership positions at Seagate Technology. He holds a Master of Business Administration from the University of Colorado, a Master of Science in Mechanical Engineering from Purdue University, and a Bachelor of Mechanical Engineering degree from PSG College of Technology.

Karen Boje Pedersen, MD
Global Medical Director, Icodec & Insulin Pipeline, Global Medical Affairs Diabetes, Novo Nordisk

Dr. Karen Boje Pedersen is a Global Medical Director heading up the Global Medical Affairs responsible for insulin icodec and the insulin pipeline at Novo Nordisk. She completed medical school at University of Copenhagen, where she also received her board certification in endocrinology and internal medicine. During her tenure in clinical practice, Karen Boje Pedersen was associated with Hillerød Hospital as chief physician with responsibilities both within diabetes and the full spectrum of endocrine disorders. She has served as board member for the Danish Society of Internal Medicine, as chair of the Education Committee in the Danish Society of Internal Medicine and as board member of the Education Committee for the Danish Endocrine Society. Dr. Pedersen joined Novo Nordisk in 2018 and has since been involved across the diabetes portfolio.

Paul V. Tomasic, MD, MS, FACP, FACE
US Medical Cardiovascular, Renal & Metabolic Senior Field Physician, AstraZeneca Pharmaceuticals

Dr. Paul Tomasic is a US Medical Cardiovascular, Renal & Metabolic Senior Field Physician with AstraZeneca Pharmaceuticals. Certified in Internal Medicine, as well as Endocrinology, Diabetes, and Metabolism, Dr. Tomasic practiced clinical endocrinology in Las Vegas, Nevada from 2005 until he joined AstraZeneca in 2018. Prior to that, he had a 25-year career in the US Navy and was medical director at duty stations around the world before retiring at the rank of Navy Captain. He earned his medical degree from the Uniformed Services University of the Health Sciences, F. Edward Hebert School of Medicine, in Bethesda, Maryland. He completed his residency in Internal Medicine at the Naval Hospital, San Diego, California and his fellowship in Endocrinology, Diabetes & Metabolism at the National Naval Medical Center in Bethesda, Maryland. Dr. Tomasic also holds several degrees and certifications in information systems and business management and had held several leadership roles with the American Association of Clinical Endocrinologists and the Health Information and Management Systems Society.

MODERATOR

Alan Moses, MD, FACP
Board Chair, The diaTribe Foundation | Past Chief Medical Officer, Joslin Diabetes Center and Novo Nordisk

Dr. Alan Moses is an independent consultant for the pharmaceutical and biotechnology sector. Trained in internal medicine and endocrinology, he spent the major part of his academic career at Harvard doing bench and clinical research and clinical care and rising to a position of Professor of Medicine. Dr. Moses co-founded and directed the Clinical Investigator Training Program at Beth Israel Deaconess-Harvard Medical School-MIT. From 1998 to 2004, Dr. Moses served as Senior Vice President and Chief Medical Officer of the Joslin Diabetes Center with specific responsibility for the Joslin Clinic. He joined Novo Nordisk in 2004. During his 14 years at Novo Nordisk, Dr. Moses served in multiple roles beginning as Associate Vice President of Medical Affairs in the US and rising to the position of Senior Vice President and Global Chief Medical Officer working in Copenhagen. Dr. Moses earned his MD from the Washington University School of Medicine in St. Louis, worked for three years at the National Institutes of Health, completed his clinical endocrine/diabetes training at Tufts New England Medical Center, and studied Health Care Strategy at Harvard Business School. He retired from Novo Nordisk in June 2018. He has been a member of the Board of Directors of The diatribe Foundation since September 2018.